Additionally, the nanotherapeutic platform successfully delivered fractionated radiotherapeutics, and we believe this nanotheranostic lays the foundation to be developed further for the future treatment and diagnostic of NIS-expressing cancers. This evidence concerns the gene SLC5A5 and cancer.